Interleukin-10 levels in Epstein-Barr virus-associated nasopharyngeal carcinoma
- PMID: 12542255
Interleukin-10 levels in Epstein-Barr virus-associated nasopharyngeal carcinoma
Abstract
The aim of this study was to determine the levels of interleukin-10 in patients with nasopharyngeal carcinoma. Both biopsies and sera were obtained from patients with nasopharyngeal carcinoma as well as Epstein-Barr virus-seronegative patients as a control. Nasopharyngeal carcinoma patients were classified using the World Health Organization pathological assessment and clinical staging of nasopharyngeal carcinoma. The numbers of interleukin-10 positive cells and the levels of serum interleukin-10 were assessed by immunohistochemical methods and enzyme-linked immunosorbent assay, respectively. The levels of serum interleukin-10 were determined by enzyme-linked immunosorbent assay. The results showed that the number of interleukin-10 positive cells and serum interleukin-10 levels were significantly increased in patients with nasopharyngeal carcinoma-World Health Organization type III and with clinical late stage (p<0.05), suggesting that interleukin-10 may have a crucial role in the progression of nasopharyngeal carcinoma.
Similar articles
-
Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.Cancer. 2003 Jul 15;98(2):288-91. doi: 10.1002/cncr.11496. Cancer. 2003. PMID: 12872347
-
Cytokine levels in patients with Epstein-Barr virus associated laryngeal carcinoma.J Laryngol Otol. 2010 Sep;124(9):990-4. doi: 10.1017/S0022215110001416. Epub 2010 Jun 8. J Laryngol Otol. 2010. PMID: 20529393
-
Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.J Clin Microbiol. 2006 Apr;44(4):1459-67. doi: 10.1128/JCM.44.4.1459-1467.2006. J Clin Microbiol. 2006. PMID: 16597877 Free PMC article.
-
Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma.Cancer Treat Rev. 2007 Oct;33(6):499-505. doi: 10.1016/j.ctrv.2007.04.007. Epub 2007 Jun 4. Cancer Treat Rev. 2007. PMID: 17544585 Review.
-
[Diagnostic evaluation of nasopharyngeal carcinoma: role of Epstein-Barr virus].An Otorrinolaringol Ibero Am. 2002;29(1):71-91. An Otorrinolaringol Ibero Am. 2002. PMID: 11962004 Review. Spanish.
Cited by
-
A pooled analysis of the IL-10-1082 A/G polymorphism and the nasopharyngeal carcinoma susceptibility.Eur Arch Otorhinolaryngol. 2016 Apr;273(4):819-25. doi: 10.1007/s00405-014-3465-9. Epub 2014 Dec 31. Eur Arch Otorhinolaryngol. 2016. PMID: 25547230 Review.
-
Nasopharyngeal carcinoma-associated inflammatory cytokines: ongoing biomarkers.Front Immunol. 2024 Oct 17;15:1448012. doi: 10.3389/fimmu.2024.1448012. eCollection 2024. Front Immunol. 2024. PMID: 39483474 Free PMC article. Review.
-
Association between IL-10 polymorphisms (-1082A/G, -592A/C and -819T/C) and oral cancer risk.Int J Clin Exp Med. 2015 Aug 15;8(8):13187-94. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26550242 Free PMC article.
-
Antibodies to human IL-10 neutralize ebvIL-10-mediated cytokine suppression but have no effect on cmvIL-10 activity.Virus Res. 2010 Nov;153(2):265-8. doi: 10.1016/j.virusres.2010.08.012. Epub 2010 Aug 20. Virus Res. 2010. PMID: 20728483 Free PMC article.
-
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.J Transl Med. 2009 Jun 17;7:45. doi: 10.1186/1479-5876-7-45. J Transl Med. 2009. PMID: 19534815 Free PMC article.